Drescher CW - Search Results

1

Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.

Urban N, Hawley S, Janes H, Karlan BY, Berg CD, Drescher CW, Manson JE, Palomares MR, Daly MB, Wactawski-Wende J, O'Sullivan MJ, Thorpe J, Robinson RD, Lane D, Li CI, Anderson GL. Urban N, et al. Among authors: drescher cw. Gynecol Oncol. 2015 Nov;139(2):253-60. doi: 10.1016/j.ygyno.2015.08.024. Epub 2015 Sep 3. Gynecol Oncol. 2015. PMID: 26343159 Free PMC article.

2

Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening.

Urban N, Drescher C, Etzioni R, Colby C. Urban N, et al. Control Clin Trials. 1997 Jun;18(3):251-70. doi: 10.1016/s0197-2456(96)00233-4. Control Clin Trials. 1997. PMID: 9204225

3

Reported ovarian cancer screening among a population-based sample in Washington state.

Drescher C, Holt SK, Andersen MR, Anderson G, Urban N. Drescher C, et al. Obstet Gynecol. 2000 Jul;96(1):70-4. doi: 10.1016/s0029-7844(00)00849-8. Obstet Gynecol. 2000. PMID: 10862845

4

A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.

Brown JV 3rd, Peters WA 3rd, Rettenmaier MA, Karlan BY, Dillman RA, Smith MR, Drescher CW, Micha JP. Brown JV 3rd, et al. Among authors: drescher cw. Gynecol Oncol. 2000 Dec;79(3):495-8. doi: 10.1006/gyno.2000.6006. Gynecol Oncol. 2000. PMID: 11104627 Clinical Trial.

5

Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer.

Andersen MR, Peacock S, Nelson J, Wilson S, McIntosh M, Drescher C, Urban N. Andersen MR, et al. Gynecol Oncol. 2002 Apr;85(1):3-8. doi: 10.1006/gyno.2001.6556. Gynecol Oncol. 2002. PMID: 11925113

6

The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. Hellström I, et al. Cancer Res. 2003 Jul 1;63(13):3695-700. Cancer Res. 2003. PMID: 12839961

7

Compliance of average- and intermediate-risk women to semiannual ovarian cancer screening.

Drescher CW, Nelson J, Peacock S, Andersen MR, McIntosh MW, Urban N. Drescher CW, et al. Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):600-6. Cancer Epidemiol Biomarkers Prev. 2004. PMID: 15066925 Clinical Trial.

8

Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma.

McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, Hellstrom I. McIntosh MW, et al. Gynecol Oncol. 2004 Oct;95(1):9-15. doi: 10.1016/j.ygyno.2004.07.039. Gynecol Oncol. 2004. PMID: 15385104 Free PMC article.

9

Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels.

Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, Hood L, Lin B. Stewart JJ, et al. Among authors: drescher cw. Mol Cell Proteomics. 2006 Mar;5(3):433-43. doi: 10.1074/mcp.M500140-MCP200. Epub 2005 Nov 30. Mol Cell Proteomics. 2006. PMID: 16319398 Free article.

10

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.

Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML. Goodell V, et al. Among authors: drescher cw. J Clin Oncol. 2006 Feb 10;24(5):762-8. doi: 10.1200/JCO.2005.03.2813. Epub 2006 Jan 3. J Clin Oncol. 2006. PMID: 16391298

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters